Suppr超能文献

哌拉西林/他唑巴坦及其他广谱抗生素对不列颠群岛住院患者体内细菌的体外活性

In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles.

作者信息

Livermore D M, Mushtaq S, James D, Potz N, Walker R A, Charlett A, Warburton F, Johnson A P, Warner M, Henwood C J

机构信息

Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, 61 Colindale Avenue, London NW9 5HT, UK.

出版信息

Int J Antimicrob Agents. 2003 Jul;22(1):14-27. doi: 10.1016/s0924-8579(03)00108-0.

Abstract

Piperacillin/tazobactam is used for empirical therapy of severe and complex infections. We assessed its activity, 9 years after launch, against consecutive, clinically significant isolates from in-patients in UK and Ireland. Standardised disc susceptibility tests were performed on 5031 isolates at 28 hospitals. For quality assurance purposes, 5% of these isolates were collected centrally for MIC tests, as were those with exceptional resistances. Compared with a similar pre-launch survey in 1991, there were major increases in the proportions of Staphylococcus aureus, Pseudomonas aeruginosa, beta-haemolytic streptococci and Enterococcus faecium isolates collected, balanced by decreases in Escherichia coli, Proteus mirabilis and coagulase-negative staphylococci. These changes in species prevalence mostly favoured organisms with inherent resistance(s) or-in the case of S. aureus-reflected the massive increase of MRSA, up from 0.7% of all isolates in 1991 to 14.8% in 2001. Based on the disc tests, piperacillin/tazobactam retained activity against 87% of Enterobacteriaceae isolates, 95% of P. aeruginosa, 99% of streptococci and 96% of Enterococcus faecalis. Resistance nevertheless had increased since 1991 in E. coli from 4 to 10%, Klebsiella spp. (5 to 21%) and in AmpC-inducible Enterobacteriaceae (17 to 23%), though not in P. mirabilis or P. aeruginosa. MIC tests confirmed most of the piperacillin/tazobactam resistance found by disc tests in Enterobacter spp., but indicated susceptibility for about half of the E. coli isolates recorded as resistant in disc tests. This situation might be remedied by reducing the zone breakpoint, but this would increase the "false susceptible" rate unacceptably. Thus, if disc tests suggest that an isolate is marginally resistant to piperacillin/tazobactam and the drug is sought as therapy, it is recommended that MIC be determined with, e.g., an Etest.

摘要

哌拉西林/他唑巴坦用于严重和复杂感染的经验性治疗。我们在其上市9年后,评估了它对英国和爱尔兰住院患者连续分离出的具有临床意义的菌株的活性。在28家医院对5031株菌株进行了标准化纸片药敏试验。为保证质量,这些菌株的5%被集中收集用于MIC试验,具有特殊耐药性的菌株也如此。与1991年上市前的一项类似调查相比,收集到的金黄色葡萄球菌、铜绿假单胞菌、β溶血性链球菌和粪肠球菌菌株比例大幅增加,同时大肠杆菌、奇异变形杆菌和凝固酶阴性葡萄球菌比例下降,二者相互平衡。这些菌种流行情况的变化大多有利于具有固有耐药性的微生物,或者就金黄色葡萄球菌而言,反映了耐甲氧西林金黄色葡萄球菌的大量增加,从1991年所有分离菌株的0.7%增至2001年的14.8%。根据纸片试验,哌拉西林/他唑巴坦对87%的肠杆菌科菌株、95%的铜绿假单胞菌、99%的链球菌和96%的粪肠球菌仍有活性。然而,自1991年以来,大肠杆菌的耐药性从4%增至10%,克雷伯菌属(从5%增至21%)以及产AmpC酶的肠杆菌科细菌(从17%增至23%)的耐药性有所增加,不过奇异变形杆菌和铜绿假单胞菌的耐药性未增加。MIC试验证实了纸片试验发现的大多数肠杆菌属菌株对哌拉西林/他唑巴坦的耐药性,但表明纸片试验记录为耐药的大肠杆菌分离株中约有一半对其敏感。这种情况可通过降低抑菌圈断点来纠正,但这会使“假敏感”率增加到不可接受的程度。因此,如果纸片试验表明某分离株对哌拉西林/他唑巴坦有边缘耐药性且寻求该药物进行治疗,建议例如用Etest法测定MIC。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验